https://resolution-tx.com/resolution-therapeutics-announces-a-26-6m-series-a-financing-from-syncona-ltd/2022-06-30T08:47:48+01:00https://resolution-tx.com/resolution-fighting-fibrosis-with-macrophages/2026-09-11T18:12:07+01:00https://resolution-tx.com/resolution-therapeutics-appoints-lisa-bright-to-its-board-of-directors/2022-06-30T08:46:47+01:00https://resolution-tx.com/resolution-therapeutics-strengthens-its-team-with-two-new-appointments/2022-06-30T08:45:21+01:00https://resolution-tx.com/resolution-therapeutics-announces-a-10m-extended-series-a-financing-from-syncona-ltd/2022-04-04T17:07:42+01:00https://resolution-tx.com/resolution-therapeutics-and-pancella-inc-announce-a-research-evaluation-option-agreement-to-develop-ipsc-derived-macrophage-cell-therapy-for-inflammatory-organ-disease/2022-04-05T08:14:23+01:00https://resolution-tx.com/resolution-therapeutics-appoints-dr-amol-ketkar-as-chief-development-officer/2022-06-30T08:43:12+01:00https://resolution-tx.com/resolution-therapeutics-appoints-bill-symonds-to-its-board-of-directors/2024-11-09T20:21:53+00:00https://resolution-tx.com/resolution-therapeutics-and-ccrm-sign-collaboration-agreement-to-develop-and-scale-up-manufacturing-for-induced-pluripotent-stem-cell-ipsc-derived-macrophage-cell-therapies/2024-11-09T20:21:46+00:00https://resolution-tx.com/resolution-therapeutics-announces-the-appointment-of-lisa-bright-as-chairman-of-its-board-of-directors/2024-11-09T20:21:33+00:00https://resolution-tx.com/resolution-expands-its-cmc-capabilities-with-key-hires/2024-11-09T20:21:27+00:00https://resolution-tx.com/resolution-appoints-liver-disease-expert-dr-clifford-a-brass-as-chief-medical-officer/2024-11-09T20:21:22+00:00https://resolution-tx.com/resolution-therapeutics-strengthens-its-team-with-senior-appointments/2024-11-09T20:21:16+00:00https://resolution-tx.com/resolution-therapeutics-strengthens-its-executive-team-with-the-appointment-of-simon-ramsden-as-chief-financial-officer/2024-11-09T20:21:11+00:00https://resolution-tx.com/resolution-therapeutics-appoints-dr-amir-hefni-as-chief-executive-officer/2024-11-09T20:20:40+00:00https://resolution-tx.com/resolution-therapeutics-founders-present-clinical-proof-of-concept-for-macrophage-cell-therapy-in-end-stage-liver-disease-at-aasld/2024-11-09T20:20:24+00:00https://resolution-tx.com/resolution-therapeutics-to-participate-in-the-jefferies-new-york-2024/2024-11-09T20:20:02+00:00https://resolution-tx.com/resolution-announces-new-data-easl-congress-2024/2024-11-09T20:19:57+00:00https://resolution-tx.com/resolution-ceo-dr-amir-hefni-talks-about-upcoming-easl-presentations-on-optimum-tv/2026-09-11T18:11:27+01:00https://resolution-tx.com/resolution-therapeutics-announces-new-breakthrough-clinical-data-for-macrophage-cell-therapy-in-end-stage-liver-disease-at-easl-2024/2024-11-09T20:19:48+00:00https://resolution-tx.com/resolution-therapeutics-to-host-virtual-webinar-on-liver-disease-with-world-leading-hepatologist-arun-sanyal-m-d/2025-09-30T12:22:22+01:00https://resolution-tx.com/resolution-therapeutics-receives-mhra-approval-to-commence-phase-i-ii-emerald-study-for-lead-candidate-rtx001/2024-11-09T20:19:24+00:00https://resolution-tx.com/resolution-therapeutics-rd-webinar/2025-10-01T09:15:20+01:00https://resolution-tx.com/resolution-therapeutics-announces-upcoming-presentations-at-the-american-association-for-the-study-of-liver-disease-aasld-the-liver-meeting-2024/2024-11-09T20:22:14+00:00https://resolution-tx.com/series-b-new-chair/2024-11-09T20:18:53+00:00https://resolution-tx.com/clinical-preclinical-data-aasld-2024/2024-11-09T20:18:25+00:00https://resolution-tx.com/resolution-therapeutics-announces-approval-of-clinical-trial-application-by-aemps-to-expand-phase-1-2-emerald-study-of-rtx001-into-spain/2024-11-19T16:38:41+00:00https://resolution-tx.com/resolution-therapeutics-announces-presentation-at-keystone-symposia-on-fibrosis/2025-09-02T21:15:06+01:00https://resolution-tx.com/nature-medicine-publishes-macrophage-cell-therapy-clinical-proof-of-concept-data-from-the-match-study/2025-01-17T09:30:38+00:00https://resolution-tx.com/resolution-therapeutics-announces-regenerative-macrophage-therapy-rmt-manufacturing-process-candidate-testing-suite-at-asgct-2025/2025-09-02T21:10:26+01:00https://resolution-tx.com/cellular-origins-cell-and-gene-therapy-catapult-and-resolution-therapeutics-form-consortium-to-deliver-fully-automated-robotics-cgt-manufacturing-platform/2025-07-15T14:53:17+01:00https://resolution-tx.com/resolution-therapeutics-to-host-virtual-rd-webinar-alongside-world-leading-clinical-hepatologists-prof-jonathan-fallowfield-and-dr-elliot-tapper/2025-09-30T12:22:08+01:00https://resolution-tx.com/first-patient-dosed-in-emerald/2025-09-02T21:49:32+01:00https://resolution-tx.com/resolution-therapeutics-appoints-lucy-singah-as-chief-financial-officer-and-daniel-kennedy-as-chief-business-officer/2025-09-11T11:48:08+01:00https://resolution-tx.com/resolution-therapeutics-rd-webinar-2025/2025-10-01T09:14:31+01:00https://resolution-tx.com/resolution-therapeutics-to-present-emerald-study-design-at-the-british-association-for-the-study-of-the-liver-basl-annual-meeting-2025/2025-10-07T10:35:54+01:00https://resolution-tx.com/resolution-therapeutics-announces-upcoming-presentations-at-the-american-association-for-the-study-of-liver-disease-aasld-the-liver-meeting-2025/2025-10-09T08:37:26+01:00https://resolution-tx.com/amir-hefni-interview-at-arms-cell-gene-meeting-on-the-mesa/2026-09-11T18:09:30+01:00https://resolution-tx.com/resolution-therapeutics-announces-new-data-showcasing-the-potential-of-regenerative-macrophage-therapy-in-treating-cirrhosis-at-aasld-2025/2025-11-07T14:08:08+00:00https://resolution-tx.com/love-your-liver-month-2026/2026-01-29T17:33:38+00:00https://resolution-tx.com/resolution-therapeutics-announces-appointment-of-louise-rowe-as-vice-president-of-operations/2026-04-01T09:04:21+01:00https://resolution-tx.com/resolutions-vp-intellectual-property-technology-strategy-eli-gilsohn-named-in-the-world-international-ip-review-wiprs-global-in-house-elite-2026-list/2026-04-10T12:38:57+01:00https://resolution-tx.com/resolution-therapeutics-to-showcase-key-preclinical-data-on-its-regenerative-macrophage-therapy-rmt-rtx001-in-oral-presentation-at-asgct-2026/2026-05-12T13:33:41+01:00https://resolution-tx.com/resolution-therapeutics-congratulates-university-of-edinburgh-on-positive-4-year-match-trial-data-on-rmt-in-liver-cirrhosis/2026-06-16T13:42:44+01:00https://resolution-tx.com/resolution-therapeutics-extends-inflammatory-and-fibrotic-disease-pipeline-with-in-vivo-regenerative-macrophage-therapy/2026-06-17T12:22:46+01:00https://resolution-tx.com/emerald-clinical-study-qa-with-dr-kushala-abeysekera-bristol-royal-infirmary-hospital/2026-08-11T12:00:43+01:00https://resolution-tx.com/the-emerald-clinical-study-an-overview-with-prof-ewan-forrest-glasgow-royal-infirmary/2026-08-28T12:29:21+01:00https://resolution-tx.com/emerald-clinical-study-qa-with-dr-paul-richardson-dr-edward-britton-royal-liverpool-university-hospital/2026-08-19T11:21:47+01:00https://resolution-tx.com/nottingham-is-investigating-a-first-in-class-cell-treatment-to-help-patients-with-end-stage-liver-disease/2026-09-11T18:08:51+01:00https://resolution-tx.com/resolution-therapeutics-partners-with-the-blood-centers-of-america-inc-to-support-broad-patient-access-to-its-experimental-regenerative-macrophage-therapy-in-the-u-s/2026-09-11T18:08:33+01:00https://resolution-tx.com/resolution-therapeutics-completes-enrollment-in-phase-i-ii-emerald-clinical-trial-evaluating-rtx001-in-end-stage-liver-disease/2026-09-10T12:24:45+01:00https://resolution-tx.com/resolution-therapeutics-to-present-interim-emerald-data-on-rtx001-as-a-late-breaker-at-aasld-2026/2026-11-03T13:50:08+00:00https://resolution-tx.com/could-regenerative-macrophage-therapy-rmt-change-the-future-of-treatment-for-patients-with-cirrhosis/2026-10-16T14:09:08+01:00https://resolution-tx.com/resolution-therapeutics-announces-positive-interim-phase-i-ii-emerald-data-for-regenerative-macrophage-therapy-rtx001-in-end-stage-liver-disease/2026-11-04T21:28:30+00:00https://resolution-tx.com/aasld-2026-qa/2026-11-05T17:38:57+00:00